Clinical study on rt-PA intravenous thrombolysis for patients with acute cerebral infarction

ObjectiveTo investigate the efficacy and safety of rt-PA(recombinant tissue plasminogen activator) intravenous thrombolysis for patients with acute cerebral infarction.Methods44 cases of acute cerebral infarction within 6 hours from the onset of stroke were divided into two groups:intravenous thrombolysis group(21 cases) and control group(23 cases).Actilyse(rt-PA) was administrated in a dose of 0.9mg/kg.8mg was injected intravenously in 2 minutes,and the rest was infused in 1 hour for intravenous thrombolysis group.The control group received only routine treatment.The evaluatation index included scoring clinical stroke scale(CSS) before treatment;24 hours,7 days,30 days and 90 days after treatment,barthel index(BI),mortality and side effects before treatment and 90 days after treatment.ResultsScoring of CSS 6 hours,24 hours,7 days,30 days and 90 days after treatment were 15.38,13.24,9.30,7.40,5.00 in intravenous thrombolysis group,and 20.65,18.78,14.90,13.00,11.95 in control group.High score of BI(95～100) at 90 days after treatment were 57.14% in intravenous thrombolysis group and 21.74% in control group.The efficacy rate and mortality rate were 76.19%,4.76% in intravenous thrombolysis group,and 30.43%,8.69% in control group.All the data show significant differences between two groups(P0.01).ConclusionEarly application of rt-PA intravenous thrombolysis is effective and safe for patients with acute cerebral infarction.